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Abstract Swiftly growing viruses are a major intimidation to human health. 
Such viruses are extremely pathogenic like Ebola virus, influenza virus, 
HIV virus, Zika virus etc . Ebola virus, a type of Filovirus, is an extremely 
infectious, single-stranded ribonucleic acid virus that infects both humans and 
apes, prompting acute fever with hemorrhagic syndrome. The high infectivity, 
severity and mortality of Ebola has plagued the world for the past fifty years 
with its first outbreak in 1976 in Marburg, Germany, and Frankfurt along with 
Belgrade and Serbia. The world has perceived about 28,000 cases and over 
11,000 losses. The high lethality of Ebola makes it a candidate for use in 
bioterrorism thereby arising more concern. New guidelines have been framed 
for providing best possible care to the patients suffering from Ebola virus 
i.e Grading of Recommendation Assessment, Development And Evaluation 
(GRADE) methodology to develop evidence-based strategy for the treatment 
in future outbreak of Ebola virus. No drugs have been approved, while many 
potent drugs like rVSV-EBOV, Favipiravir, ZMapp are on clinical test for 
human safety. In this review we will discover and discuss perspective aspects 
that lead to the evolution of different Ebola variants as well as advances in 
various drugs and vaccines for treatment of the disease.
Keywords: Filovirus; Ebola; Single-stranded ribonucleic acid; GRADE; 
vaccines; rVSV-EBOV; Favipiravir; ZMapp.
1. INTRODUCTION
The Ebola viruses (EBOV) belonging to family Filoviridae are non-segmented, 







19kbp. Firstly discovered in 1976, near to the Ebola River and prevalent regions 
of central, eastern and western Africa. Ebola is the cause for more than twenty 
lethal outbreaks of EVD (Ebola Virus Disease) having been investigated in 
Africa since 1976. A new strain known as Makona was responsible for outbreak 
in 2014. Ebola virus has been responsible for more than ten thousand deaths.
Ebola haemorrhagic fever (Ebola HF) is known globally as a fatal disease 
in humans and non-human primates (monkeys, chimpanzees and gorillas). 
Infection with the genus of Ebola causes severe and life threatening fever. Genus 
Ebola virus comprises 5 distinct species- Bundbugyo Ebola virus (BDBV), 
Zaire Ebola virus (ZEBOV), Reston Ebola virus (RESTV), Sudan Ebola virus 
(SUDV), Taï Forest Ebola virus (TAFV). BDBV, ZEBOV, and SUDV have 
been related with huge EVD outbursts in Africa (Barrette et al., 2011)(Table.1).
Table 1: Various species of Ebola (Passi et al., 2015) 
Zaire Ebola virus (ZEBOV), 
now known as Ebola (EBOV) 
virus
Zaire species of Ebola virus was responsible for its first 
outbreak in Yambuku, Zaire in the year 1976. It is the 
most dangerous species of Ebola virus resulting to highest 
number of Ebola virus related deaths. Death rate is 80-90%. 
Symptoms comprise of chilly feeling along with high fever 
similar to the symptoms of malaria.
Sudan Ebola virus (SEBOV) This Ebola virus species originated in Nzara, Sudan in 
1976. Firstly traced in cotton factory workers of Sudan, it 
simultaneously outbroke along with Zaire Ebola virus. It 
was also responsible for outbreaks in 1979, 2000 and 2004. 
The mediator of transmission for Sudan Ebola virus is still 
undiscovered and it has an average death rate of 41- 65%.
Bundibugyo Ebola virus 
(BDBV)
In 2007 and 2008 the outburst of Ebola virus disease took 
place in the Bundibugyo district of Uganda that lead to the 
discovery of a species of Ebola virus that were previously 
unknown. There were at least 100 or more Ebola virus 
sufferers with death rate of 30%. 
Ivory coast Ebola virus 
(CIEBOV) /Taï Forest Ebola 
virus (TAFV)
Ivory Coast Ebola virus was first mapped out in Tai forests 
of the Côte d’Ivoire in Africa, where a female ethnologist got 
herself accidentally infected while carrying out necropsy on 
a dead infected chimpanzee Initially in 1994, outbreak was 
amongst the wild African chimpanzees. Next outbreak of 
this virus took place in 1995, south of DRC. Its infection had 
stated only one non devastating case.
Reston Ebola virus (REBOV) This species originated in 1989 in Reston, Virginia when 
diseased monkeys were traded into Reston from Philippines. 
It has been revealed to cause disease in non-human primates 
such as monkeys, but its non pathogenic to humans. No deaths 
have been specified with this virus. Recently, Ebola Reston 
virus has been recognized very freshly in pigs in Philippines.
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Since Ebola virus evoked on 1976 in Zaire and Sudan, five different sub-
types of Ebola virus have been identified in several areas of Africa. Primarily 
affected countries within Africa – Sierra Leone, Liberia and Guinea witnessed 
overall 28616 cases causing 11310 deaths. The most recent widespread 
infection started in 2013 in West African nation of Guinea as established by 
the World Health Organization in March 2014 (Gatherer, 2014). In March 
2015, Liberia reported with 1 case over 192 contacts with a suspicion of sexual 
transmission also on June 2015 it came up with 7 cases, over 126 identified 
contacts. Ultimately, March 2016 both Liberia and Guinea were again affected 
with 13 new cases over 1200 contacts with a possibility of sexual transmission. 
On 13th of April 2016, 7 other countries (Nigeria, Mali, the United States, 
Senegal, Spain, the United Kingdom and Italy) were also reported with the 
disease and met with 36 cases, out of which 8 deaths in Nigeria, 6 in Mali 
and 1 in the United States were stated. Also eight hundred and eighty one 
healthcare workers were infected throughout this disaster and 513 died as a 
result of the disease (Shiwani et al., 2014).
3. EBOLA VIRUS DISEASE
EBOV leads to severe hemorrhagic fever resulting in lethal outcome in humans, 
and several species of non-human primates. Human Ebola outbreaks usually 
occur suddenly from a indefinite source, that spreads rapidly from person to 
person. EBOV were earlier categorized as “hemorrhagic fever viruses”, based 
on the clinical appearances, that includes coagulation defects, bleeding, and 
shock. But it’s no longer categorized as such because not all patients affected 
by Ebola developed substantial hemorrhagic symptoms, that frequently arises 
at terminal phase of fatal illness (Leroy et al., 2011).
4. RISK FACTORS AND MODE OF TRANSMISSION
Ebola Virus is transmitted to humans via close contact with the blood, secretions, 
organs or other bodily fluids of diseased animals. In Africa, infection spread 
through handling of ill or dead infected chimpanzees, gorillas, fruit bats, 
monkeys, forest antelope and porcupines. There is no possibility of infection 
with asymptomatic persons as well as there is very low risk of infection during 
the incubation period and also during the first week of symptomatic illness. 
Higher risk of transmission arises in funerals due to contact with infected 
corpse (Brainard et al., 2015). Threats of infection are also high among health 
care workers who take care of the infected, via unprotected contact with bodily 







5. CLINICAL MANIFESTATIONS 
Initial symptoms are the rapid onset of fever, weakness, muscle pain, 
fatigue, intense headache and sore throat along with vomiting, diarrhea, 
rash, symptoms of impaired kidney and liver function, abdominal pain and 
unresolved haemorrhage. Incubation period is 2 to 21 days. Other related signs 
and symptoms include conjunctival injection, chest pain, arthralgias, myalgias, 
asthenia, and hiccoughs (West & von saint, 2014; Fischer et al., 2015). Initial 
disease symptoms may be mistaken with other tropical disease such as malaria, 
dengue, or cholera. EVD causes upto 5 liters or more of watery diarrhea per 
day, continuing up to 7 days and often longer. Profuse vomiting and diarrhea 
can quickly lead to intravascular volume depletion, electrolyte disorders, 
hypoperfusion, and shock (Fowler et al., 2014). Hemorrhagic manifestations of 
Ebola are late stage complications with symptoms like petechiae, ecchymosis, 
exuding from venipuncture sites, mucosal hemorrhage, haematemesis, or 
melena (Fischer et al., 2015). Pregnant women will have impulsive abortions 
along with significant bleeding (Khan et al., 1999).
6. ACUTE NEUROLOGICAL MANIFESTATIONS
Throughout acute phase, EVD patients have number of neurological signs 
and symptoms, while serious neurological manifestations are proportionately 
unusual. Most commonly, patients will have nonspecific headache, which 
often presents as an early symptom. Altered mental status, which may range 
from mild confusion to delirium with hallucinations, may also occur, but may 
be secondary to a host of variables, including electrolyte abnormalities and 
shock. Severe cases may lead to coma (West & von saint, 2014). Meningitis 
and encephalitis associated to EVD have been recognised in recent outbreak, 
also in prior outbreaks, while the prevalence is not well noted (Sagui et al., 
2015; Howlett et al., 2016).
7. DIAGNOSIS
Diagnosis through laboratory testing show low levels of white blood cell 
and platelet along with elevated liver enzyme levels (Dallatomasina et al., 
2015). Ebola Virus Disease is distinguished from other transmittable diseases 
like malaria, typhoid fever and meningitis by using various diagnostic 
methods recommended by WHO for eg. antibody capture Enzyme-Linked 
Immunosorbent Assay (ELISA), antigen capture detection tests, serum 
neutralization test, electron microscopy, reverse transcriptase Polymerase 
Chain Reaction (PCR) assay (Drosten et al., 2003).
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8. PATHOPHYSIOLOGY OF THE DISEASE
Ebola virus invades the tissue via infected fluid that associates with mucosal or 
skin breaks, where they effectively reproduce in the monocytes, macrophages, 
and dendritic cells (Beeching et al., 2014). In vitro studies revealed that virus 
envelope made of glycoprotein is liable for both receptor binding and fusion 
with host cell membrane. The host immune attack fails to defend as heavily 
glycosylated viral envelope includes both N- and O-linked glycan providing 
protection to the virus (Ansari, 2014). The white blood cells carry the virus 
within the entire body to tissues and organs such as liver, lymph nodes, lungs 
and spleen. Presence of viral particles within the body and cell injuries caused 
by viruses promotes release of chemical signals (TNF-a, IL-6 and IL-8) 
responsible for fever and inflammation. Ebola infection damages human cells 
by causing infection to the endothelial cells that reduces reliability of the blood 
vessels and cell adhesion molecules leading to liver damage and improper 
clotting (Hensley et al., 2005).
Figure 1: Phases of Ebola Virus Infection (Gebretadik et al., 2015).
When a cell is infected with EBOV, receptors located in the cytosol 
recognizes the infectious molecule associated with virus that leads to 
activation of protein together with interferon regulatory factor 3 and factor 7 
that ultimately triggers signaling cascade and releases type 1 interferon. Type 1 







cell that further activates STAT1 and STAT2 signaling proteins that moves 
into the nucleus and triggers gene expression coding antiviral proteins (Leung 
et al., 2006). EBOV’s V24 proteins interferes with the production of antiviral 
proteins by constraining STAT1 signaling protein entry into neighboring cell 
nucleus, thus with the inhibition of these immune responses EBOV quickly 
spreads throughout the body (Volchkov et al., 2006) (Fig.1).
10. MANAGEMENT
No specific treatment for Ebola hemorrhagic fever has been approved by FDA 
yet though prospective candidates are present, being in phase 3 or waiting 
approval. Patients identified to be at risk of infection are immediately isolated 
and attended by health care personnel that have been trained in bio-safety and 
outfitted with protective equipment. All equipment utilized must be disinfected 
due the high risk of contamination from infected bodily fluids and bio-
waste should be disposed properly. Disinfection can be carried using bleach, 
detergents etc. Boiling equipment in water for 5 minutes or providing heat of 
60°C for about 1 Hour can also eliminate the virus (Cook et al., 2015). Primarily, 
supportive treatment is provided to increase survival chance of patient involving 
fluid balance maintenance, treatment of any other infections that may occur and 
symptomatic treatment (Clark et al., 2012). Supportive care guidelines for care 
of Ebola patients have been developed utilizing Grading of Recommendations 
Assessment, Development And Evaluation (GRADE) methods. 
Due to gastrointestinal fluid losses, fluid balance must be maintained 
by utilizing oral re-hydration solutions or intravenous fluids depending on 
the status of the patient (Hunt et al., 2015; MacDermott & Herberg, 2017). 
Loperamide may be utilized to decrease the fluid losses in the patient (Chertow 
et al., 2015). Electrolyte balance must be maintained by replacement and 
regular monitoring (Hunt et al., 2015). Symptomatic treatment is provided for 
various complications. Paracetamol is utilized for management of fever and 
pain, although opioid analgesics may be utilized for severe pain. Ondansetron, 
metoclopramide are utilized for nausea and vomiting. Antacids are given in 
case of dysphagia/acid reflux. Anticonvulsants (e.g., phenobarbital) used for 
management of seizures which may rarely occur. In case of agitation, sedatives 
are recommended. Hemorrhage usually occurs, thereby clotting factors and 
blood products are regularly administered. Broad spectrum antibiotics are 
utilized in case of sepsis (Clark et al., 2012). 
Also, contact tracing is performed to control the outbreak by observing 
all persons that have been in contact with the afflicted person for 21 days for 
development of signs and symptoms of Ebola Virus (EBOV) infection. In case, 
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the contact falls ill, the contact tracing is repeated for their contacts (Saurabh 
& Prateek, 2017).
11. DRUGS ON CLINICAL TESTING
Many therapies recently developed have not been fully tested until now for 
safety and efficacy (Bishop, 2015). The biggest challenge being that the virus 
needs bio-safety level 4 facilities for handling (Kortepeter et al., 2008).
11.1 Monoclonal Antibodies(mAbs) :
MB-003 is a mixture of three monoclonal antibodies c13C6, h13F6 and c6D8 
(Qiu et al., 2014). Treatment with MB-003 increased survival in animals 
infected with EBOV as it targets the surface glycoprotein of EBOV (Davidson 
et al., 2015). Another mAB, ZMAb, a combination of m1H3, m2G4 and m4G7 
monoclonal antibodies, has been used to produce protection from EBOV 
for more than 10 weeks in primates (Qiu et al., 2014). After testing the six 
monoclonal antibodies, ZMapp was created which has m2G4 and m4G7 from 
ZMAb combined with c13C6 from MB-003 (Davidson et al., 2015). It was found 
to be highly efficacious in primates but in a trial on patients in Liberia, Guinea, 
results were found to be lacking efficacy hence further research is required 
(Prevail et al., 2016). Also, a cocktail of three monoclonal antibodies isolated 
from mammalian cells, MIL-77 has been sanctioned for use on compassionate 
basis with an IND for phase-1 trial having been filed (Qiu et al., 2016).
11.2 Blood and blood products: 
Convalescent Blood and plasma have been shown to have high efficacy due 
to the fact that patients surviving Ebola disease have been known to produce 
antibodies against it. Trials done on guinea pig regarding convalescent plasma 
have shown no outstanding results but no adverse effects were noted deeming 
the treatment safe (Van Griensven et al., 2016).
11.3 Vaccines:
No vaccines have been approved by FDA for treatment of humans till date. But 
various promising candidates exist and are being tested in clinical trials.
rVSV-EBOV, the first proven vaccine to be highly effective against EBOV 
established by Public Health Agency of Canada and Merck Inc., is a vesicular 
stomatitis virus with decreased virulence, in which an Ebola virus gene has 
been added. The modification induces ZEBOV surface glycoprotein which 







high potential in preventing development of disease post exposure and except 
for joint pain, no severe adverse effects were noted. Multiple studies have 
proven its effectiveness against Ebola (Regules et al., 2017; Henao-Restrepo 
et al., 2017). The vaccine can propagate both humoral and cellular immune 
responses (Sameem & Dias, 2017).
ChAd3-ZEBOV, developed by National Institute of Allergy and Infectious 
Diseases and GlaxoSmithKline, has been derived from chimp adenovirus 
type 3 (ChAd3) and expresses glycoproteins of two Ebola virus species, 
Zaire and Sudan. This when administered produces antibodies against EBOV. 
Genetic modifications prevent the virus to replicate in humans. Single dose 
administration has been proven to be effective with only mild adverse effects 
(Ledgerwood et al., 2017). MVA-Bn-Filo has been used a booster vaccine 
along with ChAd3-ZEBOV to elongate immunity (Tapia et al., 2016).
Ad26.ZEBOV, a vaccine developed by Janssen Pharmaceutica, Johnson 
and Johnson, obtained from human adenovirus serotype 26, expresses the 
Mayinga Ebola variant glycoprotein. This is given along with a boost vaccine 
MVA-Bn-Filo. The combination causes elongated immunity up to 8 months 
(Milligan et al., 2016).
MVA-Bn-Filo (multivalent modified vaccinia Ankara) is a vaccine 
developed by Bavarian Nordic. It encodes multiple filovirus glycoproteins, 
thereby, elucidating its use along with other vaccines as a booster vaccine 
(Sridhar, 2015; Milligan et al., 2016)
Ad5.ZEBOV, developed in china, is a relatively newer vaccine utilizing 
the adenovirus type 5 vector of the more recent 2014 Zaire Guinea strain. 
Although at an early clinical stage, Phase I and II trials proved good safety 
although efficacy in humans is still not proven.
GamEvac-Combi, a combination of rVSV and Ad5, has been recently 
developed, the reason for development being the emergence of new strains of 
Ebola. It expresses the surface glycoprotein of the more recent 2014 Makona 
strain. Open phase I/II studies have proven safety and immunogenic potential 
in healthy individuals. The results justify commence of Phase III trials 
(Dolzhikova et al., 2017).
GreEMTri (Ebola-Marburg vaccine), developed in 2014 by Greffex,Inc., 
is a trivalent vaccine containing Zaire Ebola virus (ZEBOV), Sudan Ebola 
(SEBOV) and Marburg Virus (MV) genes with deleted Ad (Adenovirus) 
genes. It produces glycoprotein genes of all three Viruses, thereby, can be used 
against all three. It can target the recent variants of ZEBOV, SEBOV and MV. 
It can trigger better immune responses at lower dose and can be given through 
multiple routes (Sameem & Dias, 2017).
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rGP Nanoparticle, developed by Novavax,Inc. in 2014, is a vaccine 
containing nanoparticles of Ebola glycoprotein (EBOV GP) of Makona strain 
in a saponin based matrix adjuvant. Studies have found it highly immunogenic 
(Sharma & Ketki, 2017).
INO-4212, a DNA-based vaccine made by Inovio Pharmaceuticals and 
US Defence Advanced Research Projects Agency (DARPA) is a interleukin-12 
immune activator. It codes for both Mayinga and Makona glycoproteins. Phase 
1 studies are currently underway (Keshwara et al., 2017).
11.3 Interferons:
Interferons have a major role in immune response against viruses. Infected cells 
release interferons which then activate immune cells and halt viral replication 
by inhibiting viral gene expression. Use of modified Interferon alpha prolonged 
survival in Non Human Primates (NHP) (Bradfute, 2017). Conducted studies 
proved that interferons are moderately effective and treatment is beneficial 
only in early stages (Dyall et al., 2017).
11.4 Antivirals:
Favipiravir, formerly T-705, is a broad spectrum antiviral drug that acts 
by forming an active metabolite which prevents viral RNA replication by 
inhibiting RNA dependent RNA polymerase. Oral doses have proven effective 
against EBOV in animals even after a week post infection. In humans, however, 
highest effect was noticed in patients with moderate viral spread, but it was 
ineffective against higher level of viremia. Oral use, good tolerability and 
availability make it a viable candidate for further studies (Haque et al., 2015; 
Sissoko et al., 2016). 
Brincidofovir, an experimental drug, inhibits viral DNA polymerase, 
thereby, halting viral replication. Brincidofovir showed anti EBOV activity 
but the Phase 2 clinical trials were halted due to lack of new cases thereby 
withdrawn from investigational use (Florescu & Keck, 2014).
Galidesivir (BCX4430) is a broad spectrum antiviral drug developed 
by BioCryst Pharmaceuticals. This adenosine analogue, prevents viral RNA 
replication by inhibiting RNA Polymerase. It has shown efficacy against 
EBOV and Marbug Virus in animals while not effecting human RNA or 
DNA, thereby, Phase I study were initiated and are still ongoing. The drug 
is administered intramuscularly, but administration through oral route is also 
possible. (Warren et al., 2014; Kilgore et al., 2015).
TKM-Ebola was developed by Arbutus Biopharma as an experimental 







thereby, inhibiting replication. Effect was proven in non-human primates 
(NHP) but the drug was not able to prove efficacy in humans. After Phase 
II studies were halted due to no proof of efficacy, the company suspended 
production (Haque et al., 2015; Thi et al., 2015; Dunning et al., 2016).
AVI-7537, an antiviral developed by Sarepta Therapeutics, consists of 
phosphorodiamidate morpholino oligomers, which targets EBOV gene. The 
drug improved survival chance in NHPs that were infected. Phase 1 studies 
offered evidence of safety and pharmacokinetics but later Phase 1 studies were 
stopped due to funding issues (Heald et al., 2014; Haque et al., 2015).
JK-05, an antiviral compound developed in china, is reportedly similar to 
Favipiravir and acts by inhibiting RNA polymerase, thereby, halting replication. 
The compound has been sanctioned for emergency use and preclinical studies 
have been reportedly performed. Although no clinical data is available, China 
has been reported to have sent the drug to west Africa during the outbreak in 
2014 (Kilgore et al., 2015).
GS-5734, a novel antiviral drug developed by Gilead Sciences is a nucleoside 
pro drug that is highly potent against Filo viruses. It metabolizes into an active 
component which then constrains viral RNA replication. Treatment in NHP 
produced high efficacy and also presence of active metabolite in various organs 
suggests its potential in decreasing virion presence in bodily fluids. Its been 
used in some cases of EBOV infections in humans though the most notable 
would be its effectiveness in a newborn where GS-5734, along with ZMapp and 
covalescent blood transfusion decreased viral presence without producing any 
developmental defects (Warren et al., 2016; Dörnemann et al., 2017).
11.5 Other Drugs:
FX06, developed by MChE-F4Pharma is a human fibrin derived synthetic 
peptide currently being tested for vascular leak syndrome. The drug has been 
administered to two patients, during late stages of EBOV infection. One patient 
reportedly recovered. However no concrete data regarding efficacy is available 
(Wolf et al., 2015).
rNAPc2 (Recombinant nematode anticoagulant protein c2), an 
anticoagulant that inhibits tissue factor developed from saliva of hookworm by 
Arca Biopharma, USA has been evaluated for prevention of thrombosis. The 
drug has been used to increase survival in EBOV infected NHP but still no data 
on tolerance or efficacy in humans is available (Geisbert et al., 2003).
During screening of green fluorescent protein of EBOV, various compounds 
with activity were identified out of which FGI-103, FGI-104 and FGI-106 
produced protection through prophylactic treatment in Ebola mouse model ( 
de Wit et al., 2011).
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Azithromycin, an antibiotic was tested for efficacy against EBOV. Increased 
survival was noted in mouse models however the drug was ineffective when 
given to guinea pigs (Madrid et al., 2015; Sweiti et al., 2017).
Various FDA approved drugs have been utilized in treatment of Ebola. 
Amiodarone, an antiarrythmic drug was used in one study involving Ebola 
patients in Sierra Leone which reported decreased mortality although 
effectiveness was not established. The use was justified due to inhibition of 
filo virus cell entry in preclinical studies (Turone, 2014; Sweiti et al., 2017).
Clomiphene and Toremiphene which are FDA approved Selective estrogen 
receptor modulators (SERM) used for infertility and breast cancer respectively, 
have been studied for anti-Ebola activity in mouse. These SERMs inhibited EBOV 
entry, thereby, increasing survival in mouse models (Johansen et al., 2013).
A combination therapy utilizing Atorvastatin, Irbesartan and in some cases 
Clomiphene, was reportedly given to 100 Ebola patients in Sierra Leone out 
of which only 2 deaths were reported rest survived (Fedson & Rordam, 2015).
Chloroquine, an antimalarial drug, has been indicated to have some anti-
Ebola activity by barring EBOV entry into host cells. Tests in animals produced 
increased survival (Madrid et al., 2015; Sweiti et al., 2017). Another antimalarial 
drug, Amodiaquine was used in a comparative study against lumefantrine in 
Ebola patients. The study found that patients treated with Amodiaquine had a 
better survival rate than those treated with lumefantrine, although no data on 
effectiveness of Amodiaquine was given (Gignoux et al., 2016).
12. CONCLUSION
Although the recent outbreak in Africa (2014) has been declared as an 
emergency no more by WHO, the fear of future outbreaks prompt researchers 
throughout the world to take action. Also high lethality and infectivity of 
Ebola Virus put it as a candidate for use in Bio-terrorism. This along with the 
emergence of new strains like Makona (west Africa 2014 outbreak) forced 
development of new therapeutics against the virus, through which many 
promising drugs like ZMapp, rVSV vaccine etc, have emerged. Though many 
new therapeutics have been developed or are in development, performing 
clinical trials to measure their safety and efficacy remains a huge hurdle due to 
the bio-safety level 4 status of the disease and unavailability of subjects. Even 
if future outbreaks may occur, it is needless to say that the world is much better 
equipped to handle Ebola then it was back in 2014. With Better diagnostics, 
better management and therapeutics future outbreaks will be much better 
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